Acasti Pharma Inc expected to post a loss of 14 cents a share - Earnings Preview

Grace Therapeutics

16/06/2023 13:38

* Acasti Pharma Inc  ACST.OQ   ACST.O  is expected to report
results on June 19 (estimated).
    * 
    * ​Refinitiv's mean analyst estimate for Acasti Pharma Inc
is for
a loss of 14 cents per share. 
    * The one available analyst rating on the shares is "strong
buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Acasti
Pharma Inc
is $2​, above​ its last closing price of $0.57. ​​​

This summary was machine generated June 16 at 12:38 GMT.  All
figures in Canadian dollars  unless otherwise stated